Heart failure events with rosiglitazone in type 2 diabetes: Data from the RECORD clinical trial

Aims Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increased risk of heart failure (HF) in people with type 2 diabetes. We assessed fatal and non-fatal HF events and their outcome, and identified HF predictors in the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Dia-betes) trial population. Methods and results In a multicentre, open-label study, we randomized 4447 people with type 2 diabetes on metformin or sulfonylurea mono-therapy with a mean HbA1c of 7.9 % to add-on rosiglitazone (n 2220) or to a combination of metformin and sulfonylure